Skip to main content

Table 6 Susceptibility of E. coli and P. aeruginosa isolates to commonly used antibiotics.

From: Differential outcome of an antimicrobial stewardship audit and feedback program in two intensive care units: a controlled interrupted time series study

Unit Organism and antibiotic Pre-intervention Post-intervention p-value
TNICU     
  E. coli    
  ampicillin 42/83 (51) 40/76 (53) 0.80
  cefazolin 70/83 (84) 61/76 (80) 0.50
  cefotaxime 72/83 (87) 64/76 (84) 0.65
  ciprofloxacin 68/83 (82) 60/76 (79) 0.64
  TMP-SMX 66/83 (80) 61/76 (80) 0.91
  piperacillin-tazobactam 70/83 (84) 63/76 (83) 0.81
  imipenem 85/85 (100) 76/77 (99) 0.48a
  gentamicin 77/83 (93) 70/76 (92) 0.87
  tobramycin 76/83 (92) 70/76 (92) 0.90
  P. aeruginosa    
  ceftazidime 27/30 (90) 22/23 (96) 0.62a
  ciprofloxacin 27/30 (90) 18/23 (78) 0.27a
  piperacillin-tazobactam 27/30 (90) 22/23 (96) 0.62a
  imipenem 30/30 (100) 20/23 (87) 0.076a
  gentamicin 28/30 (93) 23/23 (100) 0.50a
  tobramycin 30/30 (100) 23/23 (100) -
MSICU     
  E. coli    
  ampicillin 37/95 (39) 30/81 (37) 0.79
  cefazolin 65/95 (68) 59/81 (73) 0.52
  cefotaxime 73/95 (77) 64/81 (79) 0.73
  ciprofloxacin 46/95 (48) 49/81 (60) 0.11
  TMP-SMX 58/95 (61) 43/81 (53) 0.29
  piperacillin-tazobactam 64/95 (67) 59/80 (74) 0.36
  imipenem 93/95 (98) 81/82 (99) 1.00a
  gentamicin 76/95 (80) 73/81 (90) 0.063
  tobramycin 72/95 (76) 72/81 (89) 0.025
  P. aeruginosa    
  ceftazidime 50/64 (78) 42/58 (72) 0.46
  ciprofloxacin 58/64 (91) 41/58 (71) 0.0049
  piperacillin-tazobactam 50/64 (78) 40/58 (69) 0.25
  imipenem 51/64 (80) 41/58 (71) 0.25
  gentamicin 58/64 (91) 48/58 (83) 0.20
  tobramycin 62/64 (97) 56/58 (97) 1.00a
  1. Data are number of isolates susceptible/total number of isolates tested (%). All p-values calculated using Chi-square unless otherwise noted. A Bonferroni corrected significance threshold of 0.0033 was used. TMP-SMX, trimethoprim-sulfamethoxazole.
  2. aFisher’s Exact test